We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biotechnology. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Zhiyi Pharmaceutics
The important activity for fund was in 2018. The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 5 - 10 millions dollars.
The usual cause for the fund is to invest in rounds with 3 partakers. The meaningful sponsors for the fund in investment in the same round are Shenzhen Capital Group, Shangdong Meiyu.
| Fund Name | Location |
| Atlantic Ventures | Germany, Hessen, Kassel |
| Berkshire Group | Boston, Massachusetts, United States |
| CIMB | Kuala Lumpur, Malaysia |
| Explore Ventures | - |
| Guokai Ronghua | - |
| Hengying Capital | Beijing, Beijing, China |
| Impact Venture | England, London, United Kingdom |
| Instarto | Central, Central Region, Singapore |
| Irish Venture Capital Association | County Wicklow, Ireland, Wicklow |
| LUMO labs | Eindhoven, Noord-Brabant, The Netherlands |
| MIAX Exchange Group | New Jersey, Princeton, United States |
| Nanjing Bangsheng Touzi | China, Jiangsu, Nanjing |
| Pfeffer Capital | - |
| Provenio Capital | California, Newport Beach, United States |
| Prudence Holdings | New York, New York, United States |
| RPS Ventures | California, Palo Alto, United States |
| Safer Made | Connecticut, New Haven, United States |
| Scorpion Capital Partners | New York, New York, United States |
| The Rahn Group | Minneapolis, Minnesota, United States |
| U.S. Army Combat Capabilities Development Command Army Research Laboratory | Louisiana, Maryland, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
| $15M | 18 Feb 2020 | Shandong | |||
Zhiyi Pharmaceutics | $7M | 05 Sep 2018 | Guangdong Province |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
| $15M | 18 Feb 2020 | Shandong | |||
Zhiyi Pharmaceutics | $7M | 05 Sep 2018 | Guangdong Province |
